Home | Welcome to Contract Pharma   
Last Updated Wednesday, December 17 2014

Print

Search Results for 'Financial Report: AstraZeneca'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published August 8, 2014
Integration of BMS assets offsets losses Read More »
By Gil Roth
Published February 6, 2014
Generics drive sales down, more layoffs planned Read More »
Published October 31, 2013
Revenues, earnings fall off patent cliff Read More »
Published August 1, 2013
Generic erosion impacts results Read More »
Published April 25, 2013
Seroquel IR loss pummels revenues Read More »
Published July 26, 2012
Loss of exclusivity for key brands wallops results Read More »
Published July 19, 2012
Loss of exclusivity for key brands wallops results Read More »
Published April 23, 2007
AstraZeneca 1Q Revenues: $7 billion (+13%) 1Q Earnings: $1.6 billion (+10%) Comments: Growth in the quarter was driven by combined sales of five key products: Nexium, Seroquel, Crestor, Arimidex and Symbicort, up 17% to $3.6 billion. R&am… Read More »
Contract Pharma’s 15th Anniversary Retrospective: Then & Now
By Kristin Brooks, Contract Pharma
Published October 14, 2014
A look back at the pharma/biopharma industry and outsourcing. Read More »
Published September 25, 2014
Previously marketed products will enter $200 million U.S. market Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On